<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased fruit and vegetable consumption is associated with decreased risk of a number of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> of epithelial origin, including <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Dietary administration of lyophilized black raspberries (LBRs) has significantly inhibited chemically induced oral, esophageal, and colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>Likewise, berry extracts added to cell cultures significantly inhibited <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated processes </plain></SENT>
<SENT sid="3" pm="."><plain>Positive results in preclinical studies have supported further investigation of berries and berry extracts in high-risk human cohorts, including patients with existing premalignancy or patients at risk for <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We are currently conducting a 6-mo chemopreventive pilot study administering 32 or 45 g (female and male, respectively) of LBRs to patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE), a premalignant esophageal condition in which the <z:mpath ids='MPATH_458'>normal</z:mpath> stratified squamous epithelium changes to a metaplastic columnar-lined epithelium </plain></SENT>
<SENT sid="5" pm="."><plain>BE's importance lies in the fact that it confers a 30- to 40-fold increased risk for the development of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, a rapidly increasing and extremely deadly <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This is a report on interim findings from 10 patients </plain></SENT>
<SENT sid="7" pm="."><plain>To date, the results support that daily consumption of LBRs promotes reductions in the urinary excretion of two markers of <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:chebi fb="0" ids="34505">8-epi-prostaglandin F2alpha</z:chebi> (8-Iso-PGF2) and, to a lesser more-variable extent, 8-hydroxy-2'-deoxyguanosine (8-OHdG), among patients with BE </plain></SENT>
</text></document>